Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE39300 E1
Publication typeGrant
Application numberUS 09/880,881
Publication dateSep 19, 2006
Filing dateJun 15, 2001
Priority dateJan 28, 1993
Fee statusPaid
Publication number09880881, 880881, US RE39300 E1, US RE39300E1, US-E1-RE39300, USRE39300 E1, USRE39300E1
InventorsDavid J. Mayer, Jianren Mao
Original AssigneeVirginia Commonwealth University Medical College Of Virginia
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Inhibiting the development of tolerance to and/or dependence on an addictive substance
US RE39300 E1
Abstract
Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.
Images(11)
Previous page
Next page
Claims(17)
1. A composition comprising an addictive substance and at least one nontoxic substance that blocks the N-methyl-D-aspartate receptor or a major intracellular consequence of N-methyl-D-aspartate receptor activation, the addictive substance being selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.
2. The composition of claim 1 in sustained release dosage form.
3. A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that provides an improved effect for the addictive substance if used alone and that blocks the N-methyl-D-aspartate receptor and consists essentially of a morphinan or blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation, the addictive substance being selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.
4. A formulated pharmaceutical composition comprising an addictive substance and a non-toxic synthetic substance, the addictive substance being selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, levorphanol, methadone, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof, the non-toxic synthetic substance providing an improved effect for the addictive substance if used alone and being selected from the group consisting of dextromethorphan, dextrorphan, and pharmaceutically acceptable salts thereof.
5. A formulated pharmaceutical composition comprising an addictive substance and a non-toxic synthetic substance, the addictive substance being selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, levorphanol, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof, the non-toxic synthetic substance being a blocker of the N-methyl-D-aspartate receptor and consisting essentially of morphinans, and providing an improved effect for the addictive substance if used alone.
6. A composition according to claims 3, 4 or 5 wherein the addictive substance is selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, methadone, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof.
7. A composition according to claims 3, 4 or 5 wherein the addictive substance is selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, isomethadone, methadone, pethidine, and pharmaceutically acceptable salts thereof.
8. A composition according to claims 3, 4 or 5 wherein the addictive substance is selected from the group consisting of codeine, methadone, and pharmaceutically acceptable salts thereof.
9. A composition according to claims 3, 4 or 5 wherein the addictive substance includes morphine or a pharmaceutically acceptable salt thereof.
10. A composition according to claims 3, 4 or 5 wherein the addictive substance includes oxycodone or a pharmaceutically acceptable salt thereof.
11. A composition according to claims 3, 4 or 5 wherein the addictive substance includes hydrocodone or a pharmaceutically acceptable salt thereof.
12. A composition according to claims 3, 4 or 5 wherein the addictive substance includes oxymorphone or a pharmaceutically acceptable salt thereof.
13. A composition according to claim 3, 4 or 5 wherein the addictive substance includes hydromorphone or a pharmaceutically acceptable salt thereof.
14. A composition according to claims 3, 4 or 5, in oral dosage form.
15. A composition according to claims 3, 4 or 5, in sustained release dosage form.
16. A composition according to claims, 3, 4 or 5, in oral dosage and sustained release dosage form.
17. A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that blocks the N-methyl-D-aspartate receptor or a major intracellular consequence of N-methyl-D-aspartate receptor activation, selected from pyrroloquinoline quinone and cis- 4 -(phosphonomethyl)- 2 -piperidinecarboxylic acid, the addictive substance being selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan, racemorphan and pharmaceutically acceptable salts thereof.
Description
CROSS REFERENCE TO RELATED APPLICATION

This is a continuation of application Ser. No. 08/043,280 filed Apr. 6, 1993, now U.S. Pat. No. 5,321,012, which is a continuation-in-part of U.S. patent application Ser. No. 08/010,583, filed Jan. 28, 1993, abandoned.

BACKGROUND OF THE INVENTION

This invention relates to a composition containing an addictive substance and a component which inhibits the development of tolerance to and/or dependence on the addictive substance. More particularly, the invention relates to a composition containing an addictive substance such as morphine or codeine and at least one nontoxic substance that blocks the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that blocks at least one major intracellular consequence of NMDA receptor activation, e.g., a ganglioside such as ganglioside GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide.

Morphine is a rapid and effective drug for the treatment of severe pain but its long term administration has been limited due to its negative side effects, principally tolerance and dependence, which develop rapidly after administration. In an effort to make morphine of greater use in the treatment of pain, it has been combined with a variety of substances intended to inhibit one or more of its undesirable side effects. U.S. Pat. No. 2,770,569 describes the combination of morphine with the compound levo-d-hydroxy-N-allyl-morphinan which is said to suppress or eliminate such undesirable side reactions of morphine as depression, nausea and vomiting. U.S. Pat. No. 4,126,684 discloses reducing either the addiction liability of an addictive substance such as a narcotic analgesic or a barbiturate or the withdrawal symptoms caused by deprivation of such a substance in an addicted subject by administering the addictive substance, e.g., morphine, with a 4-amino-3-p-halophenylbutyric acid. U.S. Pat. No. 4,415,871 describes the prevention of treatment tolerance and physical dependence in chronic morphine treatment by combining the morphine with any of the specific dipeptides indicated therein. U.S. Pat. No. 5,041,446 discloses inhibiting the development of tolerance to morphine by combining the morphine with dapiprazole. U.S. Pat. No. 5,057,519 achieves a reduction in morphine tolerance by combining the morphine with a benzamide antagonist for a subtype of the serotonin receptor, 5-HT3. Trujillo et al., “Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801”, Science, 251 (4989), pp. 85-87, Jan. 4, 1991; Tanganelli et al., “Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs”, Neuroscience Letters, 122(2), pp. 270-272, Jan. 28, 1991; Marek et al., “Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat”, Brain Research, 547(1), pp. 77-81, Apr. 26, 1991; and, Marek et al., “Delayed application of MK-801 attenuates development of morphine tolerance in rats, Brain Research, 558(1), pp. 163-165, Aug. 30, 1991 discuss the role of MK-801 (the compound 5-methyl-10,11-dihydro-SH-dibenzo[a,d]cyclohepten-5,10-imine), an NMDA receptor antagonist or blocker, in reducing morphine dependence in laboratory animals. However, MK-801 has been found to be toxic and is therefore unsuitable for pharmaceutical use.

SUMMARY OF THE INVENTION

In accordance with the present invention, a composition is provided which comprises an addictive substance and at least one nontoxic substance that blocks the N-methyl-D-aspartate receptor or at least one major intracellular consequence of N-methyl-D-aspartate receptor activation.

Further in accordance with the present invention, a method of inhibiting the development of tolerance to and/or dependence on an addictive substance administered to a mammal which is liable to addiction thereto is provided which comprises administering the addictive substance to the mammal before, with or following administration to the mammal of a tolerance-reducing and/or dependence-reducing amount of at least one non-toxic substance that blocks the N-methyl-D-aspartate receptor or at least one major intracellular consequence of N-methyl-D-aspartate receptor activation.

Still further in accordance with this invention, a method of alleviating withdrawal symptoms in a mammal addicted to an addictive substance is provided which comprises administering to the addicted mammal the addictive substance before, with or following administration to the mammal of a dependence-reducing amount of at least one nontoxic substance that blocks the N-methyl-D-aspartate receptor or the intracellular consequences of N-methyl-D-aspartate receptor activation thereby alleviating withdrawal symptoms when the addictive substance is withdrawn from the mammal.

The term “nontoxic” as used herein shall be understood in a relative sense and is intended to designate any substance that has been approved by the United States Food and Drug Administration (“FDA”) for administration to humans or, in keeping with established criteria, is susceptible to approval by the FDA for administration to humans.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1-10 are graphical representations of experimental data demonstrating the effectiveness of specific nontoxic substances that block the N-methyl-D-aspartate receptor or a major consequence of N-methyl-D-aspartate receptor activation for inhibiting morphone tolerance and dependence in rats.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

A particularly important category of addictive substances with which the present invention is concerned are the narcotic analgesics, e.g., opiates, opiate derivatives, opioids and their pharmaceutically acceptable salts. Specific examples of narcotic analgesics include alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan, thebainc and pharmaceutically acceptable salts thereof. For a detailed discussion of these and other narcotic analgesics, reference may be made to Jaffe et al., “Opioid Analgesics and Antagonists” in “Goodman and Gillman's Pharmacological Basis of Therapeutics”, Goodman et al., eds. 7th ed., 1985, MacMillan and Company, New York pp. 491-531.

Other addictive substances that can be utilized herein include acetorphine, acetyldihydrocodeine, acetylmethadol, allylprodine, alphracetylmethadol, alphameprodine, alphamethadol, benzethidine, benzylmorphine, betacetylmethadol, betameprodine, betamethadol, betaprodine, clonitazene, cocaine, codeine, methylbromide, codeine-N-oxide, cyprenorphine, desomorphine, dextromoramide, diampromide, diethylthiambutene, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiamubutene, dioxaphetyl butyrate, dipipanone, drotebanol, ethanol, ethylmethylthiambutene, eton itazene, etorphine, etoxeridine, furethidine, hydromorphinol, hydroxypethidine, ketobemidone, levomoramide, levophenacylmorphan, methyldesorphine, methyldihydromorphine, morpheridine, morphine methylpromide, morphine methylsulfonate, morphine-N-oxide, myrophine, nicocodeine, nicomorphine, nicotine, noracymethadol, norlevorphanol, normethadone, normorphine, norpipanone, phenadoxone, phenampromide, phenomorphtan, phenoperidine, piritramide, pholcodine, proheptazoine, properidine, propiran, racemoramide, thebacon, trimeperidine and the pharmaceutically acceptable salts thereof.

Still other addictive substances that can be utilized in the practice of the invention include the sedatives and hypnotics, e.g., benzodiazepines such as chlordiazepoxide, chlorazepate, diazepam, flurazepam, halazepam, ketazolam, borazepam, oxazepam, prazepam, temazepam, triazolam and the pharmaceutically acceptable salts thereof, barbiturates such as amobarbital, ambobarbital, barbital, butabartital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital, talbutal, thiamylal and thiopental and the pharmaceutically acceptable salts thereof and other sedatives and hypnotics such as chloral hydrate, meprobamate, methaqualone, methyprylon and the pharmaceutically acceptable salts thereof.

By way of inhibiting the development of tolerance to and/or dependence on any of the foregoing and similarly addictive substances, the addictive substance is administered before, with or following the administration of at least one nontoxic substance that blocks the N-methyl-D-aspartate (NMDA) receptor or the intracellular consequences of N-methyl-D-aspartate receptor activation. Activation of the NMDA receptor, a subtype of excitatory amino acid receptors, induces a number of changes in the functional activity of nerve cells, and in particular, their capacity for excitability or inhibition in the presence of an addictive substance, via an increase in intracellular Ca++ concentration. The major consequences of NMDA receptor activation include the following sequences, or cascades, of events occurring within nerve cells:

    • a) translocation and activation of protein kinases such as protein kinase C→phosphorylation of substrate proteins such as cytosolic enzymes, channel proteins, receptor proteins, etc.→changes in functional activity;
    • b) initiation of early gene (c-fos, c-jun, zif-268, etc.) expression by either increased intracellular Ca++ or Ca++-activated protein kinases→expression of functional genes responsible for production of cellular enzymes (such as protein kinases), receptor proteins (such as the NMDA receptor), ion channel proteins (such as K+, Na+, Ca++ channels), neuropeptides (such as dynorphin), etc.→changes in functional activity;
    • c) Ca++/calmodulin (or other Ca++ binding proteins) induced activation of enzymes and other cellular components→activation of Ca++/calmodulin-protein kinase systems such as Ca++/calmodulin kinase II→autophosphorylation of enzymes (e.g., Ca++/calmodulin kinase II) or other functional proteins→changes in functional activity;
    • d) Ca++/calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase→production of nitric oxide→i) production of cyclic guanosine monophosphate via activation of guanosine cyclase resulting in activation of protein kinases and early gene expression; ii) direct protein modification such as enzymes, receptor and/or channel proteins; iii) lipid membrane modification and/or nucleic acid modification via scavenge of free radicals; iv) induction of neurotoxicity at higher nitric oxide levels; v) retrograde actions in adjacent neurons or glial cells such as facilitation of glutamate release/NMDA receptor activation and/or inhibition of post-synaptic NMDA receptors→changes in functional activity;
    • e) interactions with the cyclic adenosine monophosphate/protein kinase A system, the phospholipase C-inositol triphosphate-Ca++-/diacylglycerol-protein kinase system, the phospholipase A2-arachidonic acid/prostanoids/leukotrienes system→changes in functional activity induced by second messenger systems other than NMDA receptor/Ca++/Ca++-calmodulin/protein kinase systems; and,
    • f) interactions with other excitatory amino acid receptor subtypes including non-NMDA receptors and metabotropic receptors as well as intracellular events subsequent to the activation of these excitatory amino acid receptor subtypes→changes in functional activity induced by the non-NMDA and metabotropic receptor activation.

A substance that blocks the NMDA receptor will effectively prevent all of the foregoing major intracellular sequences of events from taking place. However, even with activation of the NMDA receptor, it is still possible to inhibit the development of tolerance to and/or dependence on an addictive substance by combining the addictive substance with a substance that blocks at least one of the foregoing major intracellular sequences of events. Thus, e.g., a substance that interferes with translocation and activation of protein kinase C or with calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase is also useful for the practice of this invention.

Among the nontoxic substances that block the NMDA receptor and as such are useful in the practice of the present invention are morphinans such as dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) and dextrorphan ((+)-3-hydroxy-N-methylmorphinan), their mixtures and the pharmaceutically acceptable salts thereof. Other useful nontoxic substances that block the NMDA receptor include ketamine (2-(2-chlorophenyl)-2-(methylamino)cyclohexanone), pyrroloquinoline quinone and cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid.

Nontoxic substances that block a major intracellular consequence of NMDA receptor activation and are therefore useful in the practice of the invention include inhibitors of protein kinase C such as the gangliosides, in particular, ganglioside GM1 (monosialoganglioside) and ganglioside GT1b (trisialoganglioside); amphipathic long chain bases such as sphingosine, N,N,N-trimethylsphingosine, sphinganine and psychosine; quinolyloxazole-2 -ones such as 4-methyl-5-(3-quinolinyl)- 2-(3H)-oxazolone and phenyl-5-(2-quinolinyl)-2-3(3H)-oxazolone; 1,4-bis-(amino-hydroxyalkylamino)anthraquinones such as 1,4-bis-(3-propylamino-2-hydroxypropylamino)-9,10 anthracenedione and 1,4 -bis-(3-benzylamino-2-hydroxypropylamino)-9,10 anthracenedione; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.

Additional nontoxic substances that block a major intracellular consequence of NMDA receptor activation and as such are useful in the practice of the invention include inhibitors of calmodulin such as the phenothiazines, in particular, chlorpromazine, chlorpromazine sulfoxide, prochlorperazine dimaleate, perphenazine, trifluoperazine, fluphenazine, fluphenazine enanthate, fluphenazine decanoate, thioridazine, mesoridazine besylate, piperacetazine, acetophenazine dimaleate, carphenazine dimaleate, butaperazine dimaleate and phenothiazine sulfoxide; naphthalenesulfonamides such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6-aminohexyl)-5-chloro-2-naphthalenesulfonamide and N-(6-aminohexyl)-5-bromo-2-naphthalenesul fonamide; 4 -substituted-4H,6H-pyrrolo[1, 2-a][4,1] benzoxazepines such as 1,3-dihydro-1-((1-[(4-methyl-4H,6H-pyrrolo[1,2-a][4,1] benzoxazepin-4-yl)methyl]-4-piperidinyl}-2H-benzimidazol-2-one; benzhydryls such as N-[2] (diphenylmethylthioehtyl]-2-(trifluoromethyl)benzeneethanamine, N-[2 -(bis(4 -fluorophenyl)methylthio)ethyl]-2-(trifluoromethyl)benzenethanamine and N-[2-(bis(4-fluorophenyl)methylthio)ethyl]-3-(trifluoromethyl)benzeneethanamine; tricyclic antidepressant drugs such as imipramine, 2 -chloroimipramine and amitriptyline; penfluridol; haloperidol; pimozide; clozapine; calmidazolin; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.

Administration of the composition of this invention can be in the form of a single dosage unit containing both the addictive substance and the nontoxic substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation or the two substances can be administered separately provided both are ultimately present in effective amounts in the patient. Introduction of the composition into the patient can be by way of oral administration or by intravenous, intramuscular, subcutanous, intrathecal, epidural or intracerebroventricular injection.

The preferred dosage of addictive substance and the nontoxic substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation can vary widely, e.g., from about 0.25 to about 250 mg/day, but actual amounts will vary according to the particular active substances being used, the particular formulation containing the active substances and tile state and circumstances of the host being treated. As those skilled in the art recognize, many factors that modify the action of the active substances herein will be taken into account by the treating physician such as the age, body weight, sex, diet and condition of the subject, the time of administration, the rate and route of administration, and so forth. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage determination tests in view of the experimental data provided herein.

In alleviating withdrawal symptoms in addicted subjects deprived of the addictive substance, the substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation can be administered to the subject, together with the addictive substance, at a dosage rate of about 0.25 to about 250 mg/day, again, specific dosage levels and routes of administration being selected in accordance with the subject's circumstances. As a result of this treatment, the subject will experience a reduced level of dependence on the addictive substance eventually reaching the point where total withdrawal of the substance will result in at most mild withdrawal symptoms.

The composition herein can be formulated as a liquid, powder, elixir, injectable solution, etc. Formulations for oral use can be provided as hard gelatin capsules wherein the composition is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the composition is mixed with an oleaginous medium, e.g., liquid paraffin or olive oil.

Aqueous suspensions can contain the composition in admixture with pharmaceutically acceptable excipients such as suspensing agents, e.g., sodium carboxymethyl cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrol idone, gum tragacanth and gum acacia, dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkylene oxide with fatty acids, e.g., polyoxyethylene stearate, or condensation products of ethylene oxide with long chain al iphatic alcohols, e.g., heptadecaethyleneoxycetanol, or condensation products of ethylene exide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monoleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, e.g., polyoxyethylene sorbitan monooleate. Such aqueous suspensions can also contain one or more preservatives, e.g., ethyl- or n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin or sodium or calcium cyclamate.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the composition in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, e.g., sweetening, flavoring and coloring agents, can also be present. Syrups and elixirs can be formulated with sweetening agents, for example glycerol, sorbitol or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents.

The composition of this invention or either of its principal active ingredients can be provided in sustained release dosage form of which many kinds are known, e.g., as described in U.S. Pat. Nos. 4,788,055; 4,816,264; 4,828,836; 4,834,965; 4,834,985; 4,996,047; 5,071,646; and, 5,133,974, the contents of which are incorporated by reference herein.

The examples that follow are illustrative of the invention.

EXAMPLE 1

The effect of systemic dextrorphan on prevention of the development of morphine tolerance and dependence was examined in Sprague-Dawley rats weighing 350-400 gm. Morphine tolerance was developed in the rats by twice daily subcutaneous injection of 10 mg/kg morphine sulfate. The analgesic effect of the morphine was examined by using the well known tail-flick test which measures the latency of tail-flick upon radiant heat stimulation. The latency of tail-flick test is defined as the time elapsed from the onset of radiant heat to the flick of the rat's tail. In order to examine the effect of dextrorphan on the development of morphine tolerance, each morphine-treated rat also received intraperitoneal administration of either dextrorphan (1.56, 3.13, 6.25, 12.5 mg/kg, n=5/group) or saline (n=6) given 30 minutes prior to each morphine administration.

FIG. 1 shows the effects of systemic doses of dextrorphan (DEX) on tolerance to morphine analgesia produced by twice daily subcutaneous administration of 10 mg/kg morphine. Each symbol represents mean tail-flick latency scores (those above 4.5 seconds reflect analgesia) for each group of rats (N=5-6) and vertical bars are standard errors in this and the other figures. Baseline scores were between 4 and 5 seconds (at Day 0) and post-drug scores measured 1 hour after drug administration were close to 10 seconds for the first 5 days of daily drug administration. The control group (open triangles) show marked reduction in response to morphine (i.e., tolerance) at 7 and 9 days. In contrast, dextrorphan potently prevented the development of morphine tolerance as shown by no significant decreases in tail flick latencies, i.e., remaining analgesic during the whole course of repeated morphine administration. Asterisks indicate mean scores that were significantly different from those of the control group. All tested doses of dextrorphan were effective in preventing development of morphine tolerance with optimal doses ranging from 3.13 mg/kg to 12.5 mg/kg.

FIG. 2 shows the effects of systemic doses of dextrorphan on jumping, a withdrawal symptom produced by subcutaneous naloxone (2 mg/kg) in rats previously injected with morphine (10 mg/kg) twice daily for 9 days. Asterisks indicate median number of jumps in dextrorphan treatment groups (MOR+DEX) that were significantly less than that of the control group (MOR+SAL). Vertical bars refer to the range of the numbers of jumps. Thus, 3.13 and 6.25 mg/kg dextrorphan (but not 1.56 mg/kg) significantly reduced the incidence of jumping in morphine tolerant rats, a behavioral manifestation of morphine dependence, brought about following subcutaneous injection with 2 mg/kg naloxone. Thus, coadministration of dextrorphan with morphine greatly inhibits the development of both tolerance to and dependence on morphine while the analgesic effect of the morphine remains substantially unaffected.

EXAMPLE 2

The effects of ganglioside GM1 in inhibiting morphine tolerance and dependence utilizing both systemic and intrathecal treatment were evaluated. The systemic treatment procedure, including both morphine and ganglioside GM1 administration, was exactly the same as that used in the experimental work presented in Example 1 except that ganglioside GM1 was given 1 hour before each morphine administration.

As shown in FIG. 3, the tail flick latency in ganglioside GM1-treated (10, 30, 60 mg/kg, n=6/group) rats remained significantly longer than that of saline-treated rats on days 5, 7, 9, and 10 of repeated morphine administration, indicating the prevention of the development of morphine tolerance by ganglioside GM1. Although all 3 doses of ganglioside GM1 were effective, 30 and 60 mg/kg were more effective at days 9 and 10 than 10 mg/kg.

FIG. 4 shows the effects of systemic doses of ganglioside GM1 on jumping, a withdrawal symptom produced by subcutaneous naloxone (2 mg/kg) in rats previously injected with morphine (10 mg/kg) twice daily for 9 days. Asterisks indicate median number of jumps in GM1 treatment groups (M+G) that were significantly less than that of the control group (MOR+SAL). Vertical bars refer to the range of the numbers of jumps. All three doses [10 mg/kg (10); 30 mg/kg (30); 60 mg/kg (60)] of GM1 were effective with 60 mg/kg GM1 being the most effective dose tested.

EXAMPLE 3

This example demonstrates the effectiveness of ganglioside GM1 in preventing the development of morphine tolerance at the site of the spinal cord. Morphine sulfate 10 μg was delivered once daily through an intrathecal (spinal) canula implanted 5 days before the first morphine injection. Ganglioside GM1 or saline also was delivered intrathecally 30 minutes before each morphine injection.

FIG. 5 shows the effects of the intrathecal doses of ganglioside GM1 on tolerance to morphine analgesia produced by once daily intrathecal administration of 10 μg morphine. Intrathecal ganglioside GM1 was given 30 min before each morphine administration. Each symbol represents mean scores for maximal possible effects (and hence analgesia) for each group of rats (n=5-6) measured at 15, 30, 60, 90, 120, 180, and 240 minutes after morphine injection on Day 8, i.e., 24 hours following 6 consecutive daily intrathecal morphine injections. Vertical bars are standard errors. Maximal possible effects (MPE) were calculated by the formula % MPE=[(TL−BL)/(10−BL)]×100. TL: actual tail-flick latency; BL: baseline latency obtained before the first morphine injection; 10: cut-off time for radiant heat stimulation. The control group (open circle) showed marked reduction in response to morphine (i.e., tolerance) at each tested time point. In contrast, treatment with ganglioside GM1 effectively prevented the development of morphine tolerance as indicated by significantly higher maximal possible analgesia effects of morphine (160 nmol>80=40 nmol) as compared to those of saline-treated rats. Asterisks indicate mean scores that were significantly different from those of other groups.

EXAMPLE 4

The effects of ganglioside GM1 and the toxic NMDA receptor antagonist MK 801 on morphine tolerance were evaluated.

As shown in FIG. 6, treatment with ganglioside GM1 (60 mg/kg) inhibited the development of morphine tolerance to the degree equivalent to that induced by 0.3 mg/kg MK 801. However, 50% (3 out of 6) of the rats treated with 0.3 mg/kg MK 801 died before the completion of the experiment and the remaining rats in the group showed apparently poor grooming and weight loss indicating adverse effects of MK 801 on health. The rats treated with ganglioside GM1 or dextrorphan continued to appear well groomed and did not show weight loss. None of the rats in the GM1 or dextrorphan treatment groups died due to drug administration. Thus, dextrorphan and GM1 are nontoxic in contrast to MK 801 which exhibits severe cytotoxic effects and as such, is unlikely to be approved by the FDA for administration to humans.

EXAMPLES 5 AND 6

These examples illustrate the effects of the phenothiazine trifluoperazine (Example 5) and the naphthalenesulfonamide N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (Example 6) in preventing the development of morphine tolerance in rats.

Calmodulin is an intracellular colactor necessary for the nitric oxide pathway that can be initiated upon NMDA receptor activation. FIGS. 7-10 demonstrate that trifluoperazine (TFP) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W-7), both of which are calmodulin antagonists, effectively prevent the development of morphine tolerance in rats following intrathecal administration. In both cases, rats receiving once daily morphine sulfate (10 μg) and saline injection given intrathecally for 7 consecutive days developed tolerance to the analgesic effect or morphine as indicated by the reliable decrease in tail-flick latencies as compared to baseline latencies (day 1). In contrast, rats treated with TFP or W-7 (100 or 50 nmol) given immediately before each morphine administration showed a reliable analgesic effect of morphine (day 8) employing the same dose regimen used in the saline treatment group. The prevention of the development of morphine tolerance by TFP or W-7 is dose-related: 100=50 nmol>25=12.5 nmol. Each data point in FIGS. 7-10 represents the mean of a group of rats (n=6) and standard errors are shown by vertical lines. The asterisks refer to statistical differences (α=0.05) between the saline group and each other group.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2770569Oct 15, 1952Nov 13, 1956Hoffmann La RocheAnalgesic compositions
US4126684Dec 8, 1976Nov 21, 1978Ciba-Geigy Corporation4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4316888Apr 15, 1980Feb 23, 1982Nelson Research & Development Co.Method and composition of reducing pain
US4362870Mar 19, 1981Dec 7, 1982Regents Of The University Of MinnesotaSelective opioid receptor alkylating agents
US4416871Jan 11, 1982Nov 22, 1983The United States Of America As Represented By The Department Of Health And Human ServicesInhibition by peptides of tolerance to and physical dependence on morphine
US4446140Mar 29, 1982May 1, 1984Nelson Research & Development CompanyMethod and composition for treating mouth pain
US4464378Apr 28, 1981Aug 7, 1984University Of Kentucky Research FoundationMethod of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4476141Oct 27, 1983Oct 9, 1984University Of Georgia Research Foundation, Inc.Use of N-(6 aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6 aminohexyl)-5-chloro-2-naphthalenesulfonamide, and N-(6 aminohexyl)-5-bromo-2-naphthalenesulfonamide as vaginal contraceptives
US4602909Feb 7, 1983Jul 29, 1986Richter Gedeon Vegyeszeti Gyar RtVinca alkaloids
US4758559Jan 21, 1986Jul 19, 1988Ciba-Geigy CorporationPyrrolo[1,2-a] [4,1]benzoxazepine derivatives useful as calmodulin and histamine inhibitors
US4769372Jun 18, 1986Sep 6, 1988The Rockefeller UniversityMethod of treating patients suffering from chronic pain or chronic cough
US4785000Nov 16, 1987Nov 15, 1988The Rockefeller UniversityMethod of treating patients suffering from chronic pain or chronic cough
US4788055Dec 9, 1985Nov 29, 1988Ciba-Geigy CorporationResinate sustained release dextromethorphan composition
US4806543Nov 25, 1986Feb 21, 1989Board Of Trustees Of The Leland Stanford Junior UniversityAdministering enantiomer of analgesic opiod agonist or antagonist compound
US4816264Jun 6, 1986Mar 28, 1989Warner-Lambert CompanySustained release formulations
US4816450Sep 15, 1986Mar 28, 1989Duke UniversityAntiinflammatory agents, amine compounds
US4828836May 19, 1987May 9, 1989Euroceltique S.A.Controlled release pharmaceutical composition
US4834965Nov 12, 1987May 30, 1989Euroceltique, S.A.Controlled release pharmaceutical composition
US4834985May 19, 1987May 30, 1989Euroceltique S.A.Solid matric of water soluble polydextrose, cyclodextrin or cellulose ether and fatty alcohol or polyoxyalkylene glycol
US4876276Oct 26, 1987Oct 24, 1989Yissum Research Development Co. Of The Hebrew University Of Jerusalem(3S-4S)-7-hydroxy-Δ6 -tetrahydrocannabinols
US4888347Dec 24, 1986Dec 19, 1989Merck Sharp & Dohme LimitedUse of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
US4906779Aug 29, 1988Mar 6, 1990State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences UniversityN,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4912114Apr 14, 1989Mar 27, 1990Sandoz Ltd.Morphinan derivatives
US4919916Nov 21, 1988Apr 24, 1990Golwyn Daniel HAdministering phenylalkylhydrazines as monoamine oxidase inhibitors
US4924008May 4, 1989May 8, 1990American Home Products CorporationBenzobicycloalkane derivatives as anticonvulsant neuroprotective agents
US4937232May 17, 1988Jun 26, 1990Duke UniversityInhibition of protein kinase C by long-chain bases
US4942182Mar 1, 1989Jul 17, 1990Weiss Susan R BTreatment for cocaine addiction
US4959493Apr 22, 1988Sep 25, 1990Suntory LimitedCarboxycyclopropylglycine and process for producing the same
US4975430Jun 16, 1989Dec 4, 1990The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences UniversityCNQX and its analogs as therapeutics for degenerative neural diseases
US4990519Feb 23, 1990Feb 5, 1991Merrell Dow PharmaceuticalsMethod of using quinolyloxazole-2-ones as proteinkinase C inhibitors
US4994446Jan 3, 1989Feb 19, 1991Ramot - University Authority For Applied Research And Industrial Development Ltd.Drug system
US4994467May 31, 1989Feb 19, 1991Zimmerman Andrew WTreating autism and other developmental disorders in children with NMDA receptor antagonists
US4996047Nov 2, 1988Feb 26, 1991Richardson-Vicks, Inc.Sustained release drug-resin complexes
US5006510Jun 20, 1989Apr 9, 1991Ellis Wladislaw VAntinociceptive for burningpain or hyperesthesia
US5013540Nov 30, 1989May 7, 1991Board Of Regents, The University Of Texas SystemN-Methyl-D-aspartate, neuronal tissue
US5023239May 11, 1987Jun 11, 1991Mect CorporationSialosyl cholesterol, process for producing the same, and neuropathy remedy comprising the same
US5028611Jun 29, 1989Jul 2, 1991The Regents Of The University Of MinnesotaTreatment for cocaine use
US5028707Nov 20, 1989Jul 2, 1991Board Of Regents, University Of Texas4-hydroxyquinaldic acid derivatives
US5034395Feb 24, 1987Jul 23, 1991Otsuka Pharmaceutical Co., Ltd.Hypotensive agents, carboxylated dihydropyridines
US5034400Oct 20, 1989Jul 23, 1991Olney John WMethod for preventing neurotoxic side effects of NMDA antagonists
US5041446Jun 6, 1989Aug 20, 1991Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.Administering dapirazole
US5047229Dec 17, 1986Sep 10, 1991Miles, Inc.Treatment of cardiovascular and cerebral toxicity using calcium modulators
US5051426Mar 27, 1990Sep 24, 1991Parnell Pharmaceuticals, Inc.Method for effecting withdrawal from drug dependency
US5051442Apr 25, 1990Sep 24, 1991Merrell Dow Pharmaceuticals Inc.3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
US5055481Mar 22, 1990Oct 8, 1991Wakamoto Pharmaceutical Co., Ltd.Tetrazole derivatives and aldose reductase inhibition therewith
US5057519Jun 11, 1990Oct 15, 1991Bristol-Myers Squibb Company5-HT3 antagonists: use in reducing opiate tolerance
US5068228Aug 11, 1988Nov 26, 1991Koehler GernotNervous system disorders
US5071646Nov 9, 1989Dec 10, 1991Euroceltique, S.A.Pharmaceutical ion exchange resin composition
US5075341Dec 1, 1989Dec 24, 1991The Mclean Hospital CorporationTreatment for cocaine abuse
US5091391Aug 16, 1990Feb 25, 1992University Of Pittsburgh Of The Commonwealth System Of Higher EducationMethod of resisting neurodegenerative disorders
US5093129Jan 30, 1989Mar 3, 1992E. R. Squibb & Sons, Inc.Method for treating addiction to a drug of abuse employing an ace inhibitor
US5093525Mar 2, 1990Mar 3, 1992State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences UniversityNeuroprotective agents
US5095009Jul 20, 1990Mar 10, 1992Merrell Dow Pharmaceuticals Inc.NMDA antagonists
US5106847Aug 1, 1991Apr 21, 1992Merrell Dow Pharmaceuticals Inc.Excitatory amino acid antagonists, compositions and use
US5109017Sep 26, 1990Apr 28, 1992Fisons Corporation(2-thienyl)alkylamine derivatives having neuroprotective properties
US5118675Feb 15, 1991Jun 2, 1992American Home Products CorporationTherapy for central nervous system disorders
US5124319Oct 11, 1991Jun 23, 1992American Home Products CorporationAdministering for treatment of neuropathological disorders induced by overstimulation of excitatory amino acid receptors
US5124340Jun 28, 1989Jun 23, 1992The United States Of America As Represented By The Department Of Health And Human ServicesAdministering dihydropyridine compound
US5126330Feb 1, 1991Jun 30, 1992Mect CorporationSialosyl cholesterol and neuropathy remedy comprising the same
US5133974Jan 24, 1990Jul 28, 1992Kv Pharmaceutical CompanyTime release agents formed with binders and coatings over a core
US5137889May 23, 1991Aug 11, 1992Otsuka Pharmaceutical Co., Ltd.Dihydropyridine derivatives and process for preparing the same
US5137919Dec 31, 1990Aug 11, 1992Biomembrane InstituteEffect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
US5141957Nov 5, 1990Aug 25, 1992Sphinx Pharmaceuticals Corporation1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5145842Jul 30, 1990Sep 8, 1992Alder Research Center Limited PartnershipProtein kinase c. modulators. d.
US5151360Jul 2, 1991Sep 29, 1992Biomembrane InstituteAntitumor agents or anticarcinogenic agents
US5166207Jun 17, 1991Nov 24, 1992Neurotherapeutics, Inc.Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5171752Jul 19, 1991Dec 15, 1992Akzo N.V.Treating ischemia and angina
US5183807Jun 28, 1991Feb 2, 1993Fidia S.P.A.Use of monosialoganglioside gm, to prevent the development of tolerance to the analgesic effect of morphine and related drugs
US5185329Nov 14, 1991Feb 9, 1993Bristol-Myers Squibb CompanyAzapirone compounds
US5190925Feb 3, 1992Mar 2, 1993Fidia, S.P.A.Use of gangliosides in the treatment of autonomic dysfunction in Chagas' disease
US5321012Apr 6, 1993Jun 14, 1994Virginia Commonwealth University Medical CollegeUsing nontoxic material such as dextromethorphan, trifluoro-perazine, dextrorphan
US5352683Mar 5, 1993Oct 4, 1994Virginia Commonwealth University Medical College Of VirginiaAdministering N-methyl-D-aspartate receptor antagonist
US5441982Sep 24, 1993Aug 15, 1995Itzhak; YossefAdministering nitric oxide synthase inhibitor
US5654281Apr 26, 1995Aug 5, 1997Virginia Commonwealth UniversityInhibiting the development of tolerance to and/or dependence on an addictive substance
Non-Patent Citations
Reference
1Adams et al., "Emergency Intravenous Sedation of the Delirious, Medically Ill Patient," J. Clin. Psychiatry, 49:12 Suppl., pp. 23-27 (1988).
2Ben-Eliyahu et al., "The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat," Brain Research, vol. 575, pp. 304-308 (1991).
3Bristow et al., "Subcutaneous ketamine analgesia: postoperative analgesia using subcutaneous infusions of ketamine and morphine," Annals of the Royal College of Surgeons of England, vol. 71 (1989).
4Chapman et al., "The Combination of NMDA Antagonism and Morphine Produces Profound Antinociception in the Rat Dorsal Horn," Brain Research, vol. 573, pp. 321-323 (1991).
5Dickenson et al., "Dextromethorphan and Levorphanol on Dorsal Horn Nociceptive Neurones in the Rat," Neuropharmacology, vol. 30, No. 12A, pp. 1303-1308 (1991).
6 *Disch. Apoth.-Zig. vol. 119, No. 21 (1979), p. 821, "Opiat-Rezeptoren und Endorphine".
7Haley et al., "Evidence for spinal N-Methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat," Brain Research, vol. 518, pp. 218-226 (1989).
8Hayes et al., "Pretreatment with gangliosides reduces abnormal nociceptive responses associated with a rodent peripheral mononeuropathy," Pain, vol. 48, pp. 391-396 (1992).
9Itzhak et al. "Sensitization to the Toxic Effects of Cocaine in Mice is Associated with the Regulation of N-Methyl-D-Aspartate Receptors in the Cortex", The Journal of Pharmacology and Experimental Therapeutics, vol. 262, No. 2, pp. 464-470 (1992).
10Kamei et al., "Subsensitivity to the Cough-Depressant Effects of Opioid and Nonopiod Antitussives in Morphine-Dependent Rats: Relationship to Central Serotonin Function," Pharmacology Biochemistry & Behavior, vol. 34, pp. 595-598 (1988).
11Kanamaru et al., "Ketamine infusion for Control of Pain in Patients with Advanced Cancer," pp. 1368-1371 (1990) (see English translation of abstact).
12Koyunchoglu et al., "The treatment of heroin addicts with dextromethorphan: A double-blind comparison of dextromethorphan with Chlorpromazine," International Journal of clinical Pharmacology, Therapy and Toxicology, vol. 28, No. 4 pp. 147-152 (1990).
13Koyuncuoglu et al., "Effects of MK 801 on Morphine Physical Dependence: Attenuation and Intensification," Pharmacology Biochemistry & Behavior, vol. 43, pp. 487-490 (1992).
14Koyuncuoglu et al., "Previous Chronic Blockade of NMDA Receptors Intensifies Morphine Dependence in Rats," Pharmacology Biochemistry & Behavior, vol. 39, pp. 575-579 (1991).
15Koyuncuoglu et al., "Suppression by Ketamine and Dextromethorphan of Precipitated Abstinence Syndrome in Rats", Pharmacology Biochemistry and Behavior, vol. 35, No. 4, pp. 829-832 (1990).
16Mankowitz et al., "Epidural Ketamine," SA Medical Journal, vol. 20, pp. 441-442 (1982).
17Mao et al., "Intrathecal GM1 ganglioside and local ganglioside and local nerve anesthesia reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy," Brain Research, vol. 584, pp. 28-35 (1992).
18Mao et al., "Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy," Brain Research, vol. 576, pp. 254-262 (1992).
19Mao et al., "Pain-related increases in spinal cord membrane-bound protein kinase C following peripheral nerve injury," Brain Research, vol. 588, pp. 144-149 (1992).
20Mao et al., "Post-injury treatent with GM1 ganglioside reduces nociceptive behaviors and spinal cord metabolic activity in rats with experimental peripheral mononeuropathy," Brain Research, vol. 584, pp. 18-27 (1992).
21Marek et al., "Delayed application of MK-801 attenuates development of morphine tolerance in rats," Brain Research, vol. 558, pp. 163-165 (1991).
22Marek et al., "Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat", Brain Research, vol. 547, pp. 77-81 (1991).
23 *Marek et al; "Brain Research, Delayed application of MIC801 . . . in rats."; vol. 558, pp. 163-165.
24Oshima et al., "Continuous subcutaneous injection of ketamine for cancer pain," Can. J. Anaesth., vol. 37:3, pp. 385-392, (1994).
25Pharma Projects, 1561 (May 1994).
26 *Pharmacol. Biochem. Behav. vol. 35, No. 4 (1990), pp. 829-832.
27 *Pharmacol. Biochem. Behav. vol. 43, No. 2 (1992), pp. 487-490.
28Sadee, "Opiat-Rezeptoren und Endorphine," Deutsche Apotheker-Zeitung, vol. 119, p. 821 (1979).
29Tanganelli et al., "Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs," Neuroscience-Letter., vol. 122, pp. 270-272, 1991.
30 *Truillo et al.; "Inhibition of Morphine . . . MIC801"; Science; vol. 251, pp. 84-87.
31Trujillo et al., "Inhibition of Morphine Tolerance and Dependence by the NMDA Receptor Antagonist MK-801," Science, vol. 251, pp. 85-87 (1991).
32Ventafridda et al., "Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man," Pain, vol. 43, pp. 155-162 (1990).
Classifications
U.S. Classification514/25, 514/223.5, 514/306, 514/224.5, 514/812, 514/225.5, 514/216, 514/307, 514/282, 514/304, 514/231.2, 514/305
International ClassificationA61K31/54, A61K31/44, A61K31/445, A61K31/485, A61K31/70
Cooperative ClassificationA61K31/485
European ClassificationA61K31/485
Legal Events
DateCodeEventDescription
Feb 21, 2008FPAYFee payment
Year of fee payment: 12